SCHEMBL433529

SCHEMBL433529

CCC(N)CCCNCCC(N)CC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
GLA P06280 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
CYP1A2 P05177 2/20 0.35
CA12 O43570 2/20 0.32
CA2 P00918 2/20 0.32
CA4 P22748 2/20 0.32
CA6 P23280 2/20 0.32
CA5A P35218 2/20 0.32
CA7 P43166 2/20 0.32
CA9 Q16790 2/20 0.32
CA14 Q9ULX7 2/20 0.32
CA5B Q9Y2D0 2/20 0.32
CA3 P07451 1/20 0.32
CASP2 P42575 2/20 0.31
F13A1 P00488 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8850832 0.91 TSHR (0.42) CYP2C19MEN1KMT2AALDH1A1TSHR
SCHEMBL28111017 0.90 HRH3 (0.39) CYP2C19MEN1KMT2AALDH1A1TSHR
SCHEMBL28855173 0.89 HRH3 (0.33) CYP2C19MEN1KMT2AALDH1A1TSHR
SCHEMBL19214781 0.88 TSHR (0.46) CYP2C19MEN1KMT2AALDH1A1TSHR
SCHEMBL14163240 0.86 CA12 (0.50) CYP2C19MEN1KMT2AALDH1A1TSHR
SCHEMBL25989954 0.86 TSHR (0.56) CYP2C19ALDH1A1TSHRCYP1A2
SCHEMBL17965440 0.86 CYP2C19 (0.48) CYP2C19MEN1KMT2AALDH1A1TSHR
SCHEMBL22450950 0.86 CYP2C19 (0.48) CYP2C19MEN1KMT2AALDH1A1TSHR
SCHEMBL8510461 0.85 ALDH1A1 (0.54) ALDH1A1TSHR
SCHEMBL3158951 0.85 CA12 (0.48) CYP2C19MEN1KMT2ATSHRGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937235-A2 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS Pathologica, LLC. (US) 2008-07-02 EP claimed
US-20070078187-A1 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS PATHOLOGICA, LLC. (US) 2007-04-05 US claimed
WO-2007035957-A2 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS PATHOLOGICA, LLC. (US) 2007-03-29 WO claimed
US-7087648-B1 Methods for modulating macrophage proliferation using polyamine analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-08-08 US claimed
US-20050159493-A1 Methods for modulating macrophage proliferation using polyamine analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2005-07-21 US claimed
JP-2001520990-A 2001-11-06 JP claimed
EP-1027040-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS The Regents of the University of California (US) 2000-08-16 EP claimed
WO-1999021542-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-05-06 WO claimed
EP-3831372-A1 MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS Pathologica LLC (US) 2021-06-09 EP disclosed
US-20210085625-A1 CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG PATHOLOGICA LLC 2021-03-25 US disclosed
US-10881626-B2 Controlled release oral pharmaceutical dosage forms comprising MGBG PATHOLOGICA LLC (US) 2021-01-05 US disclosed
US-20190224144-A1 METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING PATHOLOGICA LLC 2019-07-25 US disclosed
US-10350178-B2 Methods and compositions for treatment of demyelinating diseases PATHOLOGICA LLC (US) 2019-07-16 US disclosed
US-10292950-B2 Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing PATHOLOGICA LLC (US) 2019-05-21 US disclosed
US-20050256207-A1 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs PROMAC TECHNOLOGIES, LLC 2005-11-17 US disclosed
US-20050159493-A1 Methods for modulating macrophage proliferation using polyamine analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2005-07-21 US disclosed
US-20040224037-A1 Devastating treatment against hiv/aids with capsaicin ROMERO-MATOS GONZALO 2004-11-11 US disclosed
US-20030175832-A1 Methods for monitoring and treating amyotrophic lateral sclerosis PATHOLOGICA, LLC 2003-09-18 US disclosed
EP-1027040-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS The Regents of the University of California (US) 2000-08-16 EP disclosed
WO-1999021542-A2 METHODS FOR MODULATING MACROPHAGE PROLIFERATION USING POLYAMINE ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256207-A1 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs ARG1, CD209, CSF1R CYP2C19 4803/4885MEN1 570/4885KMT2A 1148/4885
US-20210085625-A1 CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG SHBG, UGGT1, GCG CYP2C19 143/4885MEN1 974/4885KMT2A 4337/4885
US-20070078187-A1 METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS GLS, SHMT2, ARG2 CYP2C19 3039/4885MEN1 446/4885KMT2A 1328/4885
US-10881626-B2 Controlled release oral pharmaceutical dosage forms comprising MGBG SHBG, UGGT1, GCG CYP2C19 143/4885MEN1 974/4885KMT2A 4337/4885
US-20190224144-A1 METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING OPRK1, PTGES3, PTGES CYP2C19 281/4885MEN1 4750/4885KMT2A 4558/4885
US-20050159493-A1 Methods for modulating macrophage proliferation using polyamine analogs ARG1, MKI67, CSF1R CYP2C19 4826/4885MEN1 865/4885KMT2A 209/4885
US-10350178-B2 Methods and compositions for treatment of demyelinating diseases PMP22, MAG, GMFG CYP2C19 4252/4885MEN1 2868/4885KMT2A 3249/4885
US-10292950-B2 Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing OPRK1, PTGES3, PTGES CYP2C19 281/4885MEN1 4750/4885KMT2A 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.